Navigation Links
Inhibikase Therapeutics Elects Steven C. Gilman, Ph.D., to Board of Directors
Date:5/17/2011

ATLANTA, May 17, 2011 /PRNewswire/ -- Inhibikase Therapeutics, Inc. today announced the election Dr. Steven C. Gilman to the Board of Directors of Inhibikase Therapeutics, Inc.

(Logo: http://photos.prnewswire.com/prnh/20110517/CL02791LOGO)

Dr. Steven Gilman joined Cubist Pharmaceuticals in 2008 and currently serves as the Cubist's Executive Vice President, Research & Development and Chief Scientific Officer. Before joining Cubist Pharmaceuticals, Dr. Gilman held several positions with ActivBiotics, Inc., including Chairman of the board of directors and President and CEO. Previously Dr. Gilman worked at Millennium Pharmaceuticals, Inc., where he held a number of senior leadership roles including Vice President and General Manager, Inflammation. Additionally, Dr. Gilman served as Group Director at Pfizer Global Research and Development, where he was responsible for drug discovery of novel antibacterial agents as well as several other therapeutic areas.

Dr. Gilman currently serves on the Boards of Directors of the Massachusetts Biotechnology Association and the Massachusetts Society for Medical Research. In addition, Dr. Gilman serves on the Science and Regulatory Executive Committee of PhRMA. Dr. Gilman received his Ph.D. and M.S. degrees in microbiology from Pennsylvania State University, his post-doctoral training at Scripps Clinic and Research Foundation, and received a B.A. in microbiology from Miami University of Ohio.

Dr. Gilman joins Board members Dr. Stephen Fesik, Orrin H. Ingram, II Chair in Cancer Research at Vanderbilt University and former Vice-President for Cancer Research, Abbott Laboratories, Mr. David Gryska, former CFO of Celgene and Ms. Lisa Evren, Vice-President and Treasurer, Talisman-Energy.

"We are fortunate to add Dr. Gilman to the slate of new Board members elected in the last eight months.  Dr. Gilman's breadth of experience in pharmaceutical development and senior leadership will accelerate Inhibikase's growth and entry into the clinic on a novel platform," said Milton H. Werner, Ph.D., Inhibikase Therapeutics' President and Chief Executive Officer. "The Board is comprised of four leaders in research, development and finance whose insights will be of tremendous value as we build an innovative company and a novel treatment approach for infectious disease."

About Inhibikase Therapeutics, Inc.Inhibikase Therapeutics is transforming the way pharmaceuticals attack infectious diseases.  Its small molecule platform enables treatment of bacterial AND viral infectious disease through a common mechanism of action.  The Company's host-targeting strategy using clinically validated drugs and targets treat disease with a low likelihood of stimulating resistance.  Founded in 2008 and headquartered in Atlanta, Georgia, Inhibikase Therapeutics is developing treatments for orphan indications arising from polyomaviruses, such as progressive multifocal leukoencephalopathy (PML),as well as a broad range of respiratory infectious diseases, including influenza, pneumonia and respiratory syncitial virus (RSV).Contact:  Milton H. Werner, Ph.D.President and Chief Executive OfficerInhibikase Therapeutics, Inc.(917) 494-0831
'/>"/>

SOURCE Inhibikase Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inhibikase Therapeutics Discusses New Platform for Infectious Disease Pharmaceuticals at BIOCOM 2009
2. Echo Therapeutics Appoints Christopher P. Schnittker as Chief Financial Officer
3. Healthpoint Biotherapeutics Introduces OASIS® Ultra Tri-Layer Matrix
4. Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
5. Orexigen® Therapeutics Reports First Quarter Ended March 31, 2011 Financial Results
6. Cell Therapeutics Announces Planned Reverse Stock Split; Receives NASDAQ Notice of Non-Compliance; Intends to Request Hearing
7. Echo Therapeutics Expands Into New Headquarters in Philadelphia
8. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
9. Halozyme Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference on May 12
10. Amicus Therapeutics Announces First Quarter 2011 Financial Results and Continued Progress of Development Programs
11. Nile Therapeutics Announces Dosing of First Patient in Phase I Study of Cenderitide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... , July 13, 2017 RK Logistics Group, ... of Pharmacy certification for its Fremont, CA ... solutions in the Tri-Valley and San Jose ... City of Fremont , with its Fremont Innovation ... to provide such a powerful resource to the hundreds of ...
(Date:7/12/2017)... INDIANAPOLIS , July 12, 2017  Eli Lilly and ... settlement agreement with generic companies to resolve pending patent litigation ... Virginia regarding the Cialis ® ... expire on April 26, 2020. As part of the agreement, ... on September 27, 2018. "The unit dose patent ...
(Date:7/11/2017)... 2017  The global market for liquid biopsy diagnostic ... million in 2016.  Although in early stages, the global ... particular as a result of the gradual shift towards ... introduction of a significant number of new liquid biopsy ... tumor biomarkers to guide treatment decisions. ...
Breaking Medicine Technology:
(Date:7/26/2017)... WI (PRWEB) , ... July 26, 2017 , ... The ... 2030 in the United States, but ways to improve asthma control in the population ... Clinical Immunology: In Practice (JACI: In Practice), an official journal of the American Academy ...
(Date:7/25/2017)... ... July 25, 2017 , ... Summers in Palm Springs sizzle, but there are ... homemade gourmet ice cream, sparkling pools, and mile-high fun. , At Arrive's Ice Cream ... and other must-have knick knacks. Ice cream and sorbet flavors rotate, but the classics ...
(Date:7/25/2017)... ... July 25, 2017 , ... ... of their partnership to provide the Pharmacist eCare Plan to Computer-Rx ... the country with the ability to develop the Pharmacist eCare Plan, a shared ...
(Date:7/25/2017)... ... July 25, 2017 , ... ... it will be exhibiting and providing demos of its smart journaling platform at ... Convention Center in Washington D.C. from August 3-6, 2017. , The APA Annual ...
(Date:7/25/2017)... ... July 25, 2017 , ... ... in the United States, today announced its partnership with financial technology company, Automated ... The foundation of the solution lies within Hyosung’s superior ATMs, assisted self-service devices ...
Breaking Medicine News(10 mins):